License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright
© Medicine and Pharmacy Reports, 2022
Affiliations
Dan Dumitru Pop
Department of Radiation Oncology, Medisprof Cancer Center, Cluj-Napoca
Claudiu Hopîrtean
Department of Radiation Oncology, Medisprof Cancer Center, Cluj-Napoca, Romania
Flavius Coşer
Department of Radiation Oncology, Medisprof Cancer Center, Cluj-Napoca, Romania
Florina Dan
Department of Radiation Oncology, Medisprof Cancer Center, Cluj-Napoca, Romania
Teodor Zah
IOCN Oncology Institute “Prof. Dr. Ion Chiricuta” Cluj-Napoca, Romania
Zsolt Fekete
University of Medicine and Pharmacy “Iuliu Hatieganu, Cluj-Napoca, Romania
Aurel Chiş
Department of Medical Physics, Medisprof Cancer Center, Cluj-Napoca, Romania
Gabriela Tufăscu
Department of Medical Physics, Medisprof Cancer Center, Cluj-Napoca, Romania
Adrian Udrea
Department of Medical Oncology, Medisprof Cancer Center, Cluj-Napoca, Romania
Alina Mihai
Department Radiotherapy, Beacon Hospital, Beacon Court, Sandyford. Dublin 18, Ireland
How to Cite
Implementation of advanced radiotherapy techniques: stereotactic body radiotherapy (SBRT) for oligometastatic patients with lung metastasis - a single institution experience
Abstract
Background and purpose. The treatment of oligometastatic disease has become common practice as advanced radiotherapy techniques became more available. Lung is one of the main metastatic sites for a majority of cancers and many of these patients present with a limited metastatic disease burden. For these patients, SBRT (Stereotactic Body Radiation Therapy) represents a non-invasive treatment alternative. In this report we present our experience with our first series of patients with limited metastatic disease treated with lung SBRT. The purpose of this paper is to provide a qualitative and quantitative assessment of the lung SBRT treatment process and algorithm leading up to treatment delivery in a community-based radiotherapy department.
Methods. We have retrospectively reviewed our first series of 41 patients with lung oligometastases from various malignancies, treated using SBRT between March 2019 and December 2020. Demographic, technical and outcome data were analyzed.
Results. A number of 45 lung metastases (in 41 patients) were treated with SBRT during the specified time period. The median age was 65.7 years old (range 33-83). 16 patients (39%) were treated for multiple lesions and the mean number of treated lesions was 1 (range1-3). Median dose prescribed was 50 Gy /5 fractions (median BED10 =77 Gy). The median intra-fraction displacements were: Vertical (0.23cm), Longitudinal (-0.27 cm), Lateral (-0.1 cm), Pitch [0.22°], Roll [0.15°], Rotation [0.32°]. The median session time was 40 minutes. All patients completed the prescribed course of treatment.
Preliminary clinical data were recorded. With a median follow-up of 9 months, local control was recorded in all but one patient. At the last known follow-up, local control was recorded for 39 (85%) out of 45 treated lesions.
Conclusion. For lung SBRT, the required corrections at the time of treatment delivery are small, as long as strict protocols are implemented. Preliminary data for lung metastasis in oligometastatic patients support SBRT as a viable method of achieving high rates of early local control. These results need to be further confirmed in a larger cohort of patients with longer follow-up.